Matinas Biopharma Holdings, Inc. current report, 25 September 2026

Full document

Filing summary

Company and period: Matinas BioPharma Holdings, Inc. filed this Form 8-K on September 28, 2026, reporting a corporate action approved and filed on September 25, 2026. The filing concerns its common stock, not operating or financial results.

Material corporate action

  • A 1-for-15 reverse stock split took effect at 12:01 a.m. Eastern Time on September 28, 2026. Each 15 outstanding common shares became one share.
  • The split applied uniformly and generally did not change stockholders’ percentage ownership, except where fractional shares would otherwise have resulted. No fractional shares were issued; affected holders are entitled to a proportional cash payment.
  • The common stock’s par value and the company’s authorized share count did not change. Outstanding options, warrants, convertible preferred stock, and other securities exercisable for or convertible into common stock were adjusted under their terms.
  • The common stock’s CUSIP changed to 576810 402. The company anticipated split-adjusted trading on NYSE American beginning September 28, subject to exchange approval.

Financial metrics and outlook

This 8-K provides no revenue, profit, cash flow, margin, debt, liquidity, or other operating financial metrics, and gives no financial guidance or outlook. It does not quantify the cash payments for fractional shares or the post-split share count.

Approvals and context

Stockholders approved the certificate amendment at the June 23, 2025 annual meeting. The board approved and authorized its filing on September 16, 2026. The filing identifies the reverse split as a material modification to security-holder rights and includes the certificate amendment as Exhibit 3.1.

Investor verification points

  • Confirm NYSE American approval and the effective date of split-adjusted trading.
  • Review Exhibit 3.1 for the full amendment terms and confirm how fractional-share cash payments are calculated and distributed.
  • Verify post-split share counts and adjustments to options, warrants, and convertible securities in subsequent company disclosures.